Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience

References

• Global Initiative for Asthma. Global strategy for asthma management and prevention; 2020. [accessed 2020 Sep 30]. https://ginasthma.org.
   Google Scholar
• Mincheva R, Ekerljung L, Bossios A, Lundbäck B, Lötvall J. High prevalence of severe asthma in a large random population study. J Allergy Clin Immunol. 2018;141(6):2256–2264. doi:10.1016/j.jaci.2017.07.047.
   PubMed Web of Science ®Google Scholar
• GINA. Difficult to treat & severe asthma in adolescent and adult patients. Diagnosis and management; 2019. https://ginasthma.org.
   Google Scholar
• Inoue H, Kozawa M, Milligan KL, Funakubo M, Igarashi A, Loefroth E. A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan. NPJ Prim Care Respir Med. 2019;29(1):13–20.
   PubMed Web of Science ®Google Scholar
• Israel E, Reddel HK. Severe and difficult-to-treat asthma in adults. N Engl J Med. 2017;377(10):965–976. doi:10.1056/NEJMra1608969.
   PubMed Web of Science ®Google Scholar
• Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018; 52(4):1800703. doi:10.1183/13993003.00703-2018.
   PubMed Web of Science ®Google Scholar
• Denton E, Price DB, Tran TN, Canonica GW, Menzies-Gow A, FitzGerald JM, Sadatsafavi M, Perez de Llano L, Christoff G, Quinton A, et al. Cluster analysis of inflammatory biomarker expression in the international severe asthma registry. J Allergy Clin Immunol Pract. 2021;9(7):2680–2688. doi:10.1016/j.jaip.2021.02.059.
   PubMed Web of Science ®Google Scholar
• Gauthier M, Ray A, Wenzel SE. Evolving concepts of asthma. Am J Respir Crit Care Med. 2015; 192(6):660–668. doi:10.1164/rccm.201504-0763PP.
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012; 18(5):716–725. doi:10.1038/nm.2678.
   PubMed Web of Science ®Google Scholar
• Casciano J, Krishnan JA, Small MB, Buck PO, Gopalan G, Li C, Kemp R, Dotiwala Z. Value of peripheral blood eosinophil markers to predict severity of asthma. BMC Pulm Med. 2016; 16(1):109–116. doi:10.1186/s12890-016-0271-8.
   PubMed Web of Science ®Google Scholar
• Lee Y, Park Y, Kim C, et al. Longitudinal outcomes of severe asthma: real-world evidence of multidimensional analyses. J Allergy Clin Immunol Pract. 2020;S2213(20):31105–31103.
   Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291.
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360(10):973–984. doi:10.1056/NEJMoa0808991.
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MMM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O’Byrne PM. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009; 360(10):985–993. doi:10.1056/NEJMoa0805435.
   PubMed Web of Science ®Google Scholar
• Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020; 55(5):1902420. doi:10.1183/13993003.02420-2019.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, d’Ancona G, Elstad M, Green L, Fernandes M, Thomson L, Roxas C, Dhariwal J, Nanzer AM, Kent BD, et al. Real-world effectiveness and the characteristics of a "super-responder" to mepolizumab in severe eosinophilic asthma. Chest. 2020; 158(2):491–500. doi:10.1016/j.chest.2020.03.042.
   PubMed Web of Science ®Google Scholar
• Mukherjee M, Forero DF, Tran S, Boulay M-E, Bertrand M, Bhalla A, Cherukat J, Al-Hayyan H, Ayoub A, Revill SD, et al. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Eur Respir J. 2020; 56(4):2000117. doi:10.1183/13993003.00117-2020.
   PubMed Web of Science ®Google Scholar
• Schleich F, Graff S, Nekoee H, Moermans C, Henket M, Sanchez C, Paulus V, Guissard F, Donneau A‐F, Louis R, et al. Real-world experience with mepolizumab: does it deliver what it has promised? Clin Exp Allergy. 2020; 50(6):687–695. doi:10.1111/cea.13601.
   PubMed Web of Science ®Google Scholar
• Taillé C, Chanez P, Devouassoux G, Didier A, Pison C, Garcia G, Charriot J, Bouée S, Gruber A, Pribil C, et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J. 2020; 55(6):1902345. doi:10.1183/13993003.02345-2019.
   PubMed Web of Science ®Google Scholar
• Israel E, Canonica GW, Brusselle G, et al. Real-life effectiveness of mepolizumab in severe asthma: a ­systematic literature review. J Asthma. 2021;24:1–17. doi:10.1080/02770903.2021.2008431. Epub ahead of print.
   Web of Science ®Google Scholar
• Pelaia C, Crimi C, Pelaia G, Nolasco S, Campisi R, Heffler E, Valenti G, Crimi N. Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. Clin Exp Allergy. 2020; 50(7):780–788. doi:10.1111/cea.13613.
   PubMed Web of Science ®Google Scholar
• Lombardi C, Bagnasco D, Caruso C, D’Amato M, Menzella F, Milanese M, Senna G, Canonica GW, Passalacqua G. Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulm Pharmacol Ther. 2019; 54:87–89. doi:10.1016/j.pupt.2018.12.003.
   PubMed Web of Science ®Google Scholar
• Crimi C, Campisi R, Cacopardo G, Intravaia R, Nolasco S, Porto M, Pelaia C, Crimi N. Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. World Allergy Organ J. 2020; 13(9):100462. doi:10.1016/j.waojou.2020.100462.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371(13):1198–1207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Busse W, Spector S, Rosén K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol. 2013;132(2):485–486.e11. doi:10.1016/j.jaci.2013.02.032.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, Brightling CE, Pavord ID. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016; 4(7):549–556. doi:10.1016/S2213-2600(16)30031-5.
   PubMed Web of Science ®Google Scholar
• Bourdin A, Shaw D, Menzies-Gow A, FitzGerald JM, Bleecker ER, Busse WW, Ferguson GT, Brooks L, Barker P, Gil EG, et al. Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. J Asthma. 2021;58(4):514–522. doi:10.1080/02770903.2019.1705333.
   Web of Science ®Google Scholar
• Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi:10.2147/JAA.S176026.
   PubMed Web of Science ®Google Scholar
• Huang C-C, Chang P-H, Wu P-W, Wang C-H, Fu C-H, Huang C-C, Tseng H-J, Lee T-J. Impact of nasal symptoms on the evaluation of asthma control. Medicine. 2017; 96(8):e6147. doi:10.1097/MD.0000000000006147.
   PubMed Web of Science ®Google Scholar
• Karatzanis A, Chatzidakis A, Milioni A, Vlaminck S, Kawauchi H, Velegrakis S, Prokopakis E. Contemporary use of corticosteroids in rhinology. Curr Allergy Asthma Rep. 2017;17(2):11–22. doi:10.1007/s11882-017-0679-0.
   PubMed Web of Science ®Google Scholar
• Hopkins C, Browne JP, Slack R, Lund V, Brown P. The Lund-Mackay staging system for chronic rhinosinusitis: how is it used and what does it predict? Otolaryngol Head Neck Surg. 2007; 137(4):555–661. doi:10.1016/j.otohns.2007.02.004.
   PubMed Web of Science ®Google Scholar
• Humbert M, Albers FC, Bratton DJ, Yancey SW, Liu MC, Hozawa S, Llanos J-P, Kwon N. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. Respir Med. 2019; 154:69–75. doi:10.1016/j.rmed.2019.06.004.
   PubMed Web of Science ®Google Scholar
• Sposato B, Scalese M, Camiciottoli G, Carpagnano GE, Pelaia C, Santus P, Maniscalco M, Corsico A, Grosso A, Baglioni S, et al. Mepolizumab effectiveness and allergic status in real life. Int Arch Allergy Immunol. 2021;182(4):311–318. doi: 10.1159/000511147.
   PubMed Web of Science ®Google Scholar
• Matucci A, Vultaggio A, Maggi E, Kasujee I. Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question? Respir Res. 2018;19(1):113–123. doi:10.1186/s12931-018-0813-0.
   PubMed Web of Science ®Google Scholar
• Wen T, Rothenberg ME. The regulatory function of eosinophils. Microbiol Spectr. 2016; 4(5):10–1128. doi:10.1128/microbiolspec.MCHD-0020-2015.
   Web of Science ®Google Scholar
• Berek C. Eosinophils can more than kill. J Exp Med. 2018; 215(8):1967–1969. doi:10.1084/jem.20181152.
   PubMed Web of Science ®Google Scholar
• Abdala-Valencia H, Coden ME, Chiarella SE, Jacobsen EA, Bochner BS, Lee JJ, Berdnikovs S. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease. J Leukoc Biol. 2018; 104(1):95–108. doi:10.1002/JLB.1MR1117-442RR.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Arkwright PD, Brüggen MC, Busse W, Gadina M, Guttman-Yassky E, Kabashima K, Mitamura Y, Vian L, Wu J, et al. Type 2 immunity in the skin and lungs. Allergy. 2020; 75(7):1582–1605. doi:10.1111/all.14318.
   PubMed Web of Science ®Google Scholar
• Schmid-Grendelmeier P, Altznauer F, Fischer B, Bizer C, Straumann A, Menz G, Blaser K, Wüthrich B, Simon H-U. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol. 2002; 169(2):1021–1027. doi:10.4049/jimmunol.169.2.1021.
   PubMed Web of Science ®Google Scholar
• Choi Y, Sim S, Park HS. Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications. Korean J Intern Med. 2020;35(4):823–833. doi:10.3904/kjim.2020.022.
   PubMed Web of Science ®Google Scholar